Fuzionaire Theranostics Welcomes Li Boynton to Board of Directors and Klaus Kopka to Advisory Board
2024年7月23日 - 9:00PM
ビジネスワイヤ(英語)
Additions made to Board of Directors and
Advisory Board ahead of first patient tests of GRPR-targeting PET
imaging agents and radioligand therapies to occur in Germany under
compassionate use laws
Fuzionaire Theranostics, Inc. (“Fuzionaire Tx”) announced today
that Li Boynton and Klaus Kopka, PhD have joined the company’s
Board of Directors and Advisory Board, respectively, supporting the
company’s growth into clinical development.
Ms. Boynton joins the Board of Directors following a decade in
healthcare finance. She was most recently a biopharma equity
analyst at JPMorgan Asset Management, one of the largest investment
platforms in biopharma globally, where she spent over six years
investing in biotechnology, pharmaceuticals, and specialty
pharmaceuticals across a broad range of US portfolios. Previously,
Ms. Boynton held investment roles at Guggenheim Partners and
Healthcare Royalty Partners following undergraduate immunology and
proteomics research at Yale, where she completed her B.S. in
Molecular, Cellular and Developmental Biology.
Dr. Kopka joins the Advisory Board as a full professor in
Bioinorganic and Radiopharmaceutical Chemistry at Technical
University Dresden, Germany, and Director of the Institute of
Radiopharmaceutical Cancer Research, HZDR, Germany. Previously, he
held a full professorship at Ruprecht-Karls-University of
Heidelberg and was head of the Division of Radiopharmaceutical
Chemistry at the German Cancer Research Center, DKFZ, in
Heidelberg.
Dr. Kopka is a co-inventor of fluorine-18-PSMA-1007, or
Radelumin®, and lutetium-177-PSMA-617, or
Pluvicto®. Novartis’s Pluvicto, for patients with
PSMA+ metastatic castration-resistant prostate cancer (mCRPC), is
the first and to date only approved PSMA-targeted radioligand
therapy.
Fuzionaire Tx adds Ms. Boynton’s experience in financial markets
and investing in public and private biopharmaceutical companies,
and Dr. Kopka’s expertise in radiopharmaceuticals in clinical and
academic settings prior to commercial launches, as the company’s
GRPR-targeting radiopharmaceuticals advance into first-in-patient
tests at medical centers in Germany.
Supporting the company’s GRPR-focused research and development,
collaborators of Fuzionaire Tx at McGill University and McMaster
University have been awarded a grant from the Canadian Institutes
of Health Research (CIHR). The grant will expand the company’s
developmental work on GRPR-targeting theranostic
radiopharmaceuticals using the HetSiFA® platform.
The company’s heteroaromatic silicon-fluoride acceptors, or
HetSiFAs, are modular radiolabeling moieties that enable rapid
prototyping of peptide-based theranostics, tunable albumin binding
to optimize biodistribution, manufacture of fluorine-18 PET
companions at large scale, and chemically identical therapeutic and
diagnostic pairs. The company’s HetSiFA-based radioligand therapies
use actinium-225 and other leading alpha- and beta-emitting
radionuclides.
About Fuzionaire Theranostics
Fuzionaire Theranostics is a radiopharmaceutical company on a
mission to make better and more accessible theranostic treatments
for people with cancer. With origins in Nobel laureate Robert
Grubbs' lab at Caltech, the company's patented
HetSiFA® platform enables rapid development of
radioligand therapies and companion PET diagnostics, and offers
manufacturing advantages in a clinical setting. The company’s
pipeline addresses pressing clinical needs for several types of
cancer, beginning with cancers in which gastrin-releasing peptide
receptor (GRPR) is expressed, including metastatic prostate
cancer.
For more, visit us at: www.fuzionairetx.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240723192401/en/
Rebecca Ewing 903 215 0296 Jones-Dilworth, Inc.